SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. Funds and ETFs Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Equities
002399
CNE100000P02
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.36 CNY | +9.98% |
|
+12.36% | -11.68% |
ETFs positioned on Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 117 M€ | +2.11% | - | |
| 0.00% | 31 M€ | +5.22% | - | |
| 0.00% | 34 M€ | +2.67% | - |
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based pharmaceutical company focused on the field of heparin sodium preparations and raw materials, macromolecular drugs contract development manufacturing organization (CDMO) and innovative drug development. The Companyâs main products and services include enoxaparin sodium preparations and heparin sodium bulk medicines, enoxaparin sodium bulk medicines, and CDMO services for macromolecular drugs. The Company distributes its products within the domestic market and to overseas markets, including Turkey, Brazil, the United States and others.
Sector
Pharmaceuticals
Calendar
2024-05-22
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
SELL
Number of Analysts
1
Last Close Price
10.36
CNY
Average target price
6.4
CNY
Spread / Average Target
-38.22%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -11.68% | 1.88B | |
| +21.41% | 43.48B | |
| +20.67% | 22.65B | |
| +14.86% | 14.73B | |
| +14.21% | 13.79B | |
| +48.11% | 12.04B | |
| -8.37% | 7.08B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +11.90% | 5.47B |
- Stock Market
- Equities
- 002399 Stock
- Funds and ETFs Shenzhen Hepalink Pharmaceutical Group Co., Ltd.